USRE31006E
(en)
|
1968-09-24 |
1982-08-03 |
Akzona Incorporated |
Process for the demonstration and determination of reaction components having specific binding affinity for each other
|
US3654090A
(en)
|
1968-09-24 |
1972-04-04 |
Organon |
Method for the determination of antigens and antibodies
|
NL154598B
(nl)
|
1970-11-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US4016043A
(en)
|
1975-09-04 |
1977-04-05 |
Akzona Incorporated |
Enzymatic immunological method for the determination of antigens and antibodies
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4162940A
(en)
|
1977-03-31 |
1979-07-31 |
Takeda Chemical Industries, Ltd. |
Method for producing Antibiotic C-15003 by culturing nocardia
|
US4169888A
(en)
|
1977-10-17 |
1979-10-02 |
The Upjohn Company |
Composition of matter and process
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
US4263294A
(en)
|
1978-11-20 |
1981-04-21 |
Takeda Chemical Industries, Ltd. |
Maytansinoids, pharmaceutical compositions thereof and method of use thereof
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5622790A
(en)
|
1979-07-31 |
1981-03-03 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
EP0028683A1
(de)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotikum C-15003 PHO und seine Herstellung
|
US4491632A
(en)
|
1979-10-22 |
1985-01-01 |
The Massachusetts General Hospital |
Process for producing antibodies to hepatitis virus and cell lines therefor
|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4342566A
(en)
|
1980-02-22 |
1982-08-03 |
Scripps Clinic & Research Foundation |
Solid phase anti-C3 assay for detection of immune complexes
|
EP0043718B1
(de)
|
1980-07-07 |
1984-11-28 |
National Research Development Corporation |
Zellinien
|
US4341761A
(en)
|
1980-07-25 |
1982-07-27 |
E. I. Du Pont De Nemours And Company |
Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4413132A
(en)
|
1980-11-18 |
1983-11-01 |
The Upjohn Company |
Antibiotic CC-1065 indoline intermediates
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4466917A
(en)
|
1981-02-12 |
1984-08-21 |
New York University |
Malaria vaccine
|
US4493890A
(en)
|
1981-03-23 |
1985-01-15 |
Miles Laboratories, Inc. |
Activated apoglucose oxidase and its use in specific binding assays
|
US4451570A
(en)
|
1981-03-26 |
1984-05-29 |
The Regents Of The University Of California |
Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
|
US4399121A
(en)
|
1981-11-04 |
1983-08-16 |
Miles Laboratories, Inc. |
Iodothyronine immunogens and antibodies
|
US4427783A
(en)
|
1981-12-14 |
1984-01-24 |
Hoffmann-La Roche Inc. |
Immunoassay of thymosin α1
|
US4867973A
(en)
|
1984-08-31 |
1989-09-19 |
Cytogen Corporation |
Antibody-therapeutic agent conjugates
|
US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
FR2523445A1
(fr)
|
1982-03-17 |
1983-09-23 |
Sanofi Sa |
Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
|
US4418064A
(en)
|
1982-09-29 |
1983-11-29 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4493795A
(en)
|
1983-10-17 |
1985-01-15 |
Syntex (U.S.A.) Inc. |
Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
|
AU3934085A
(en)
|
1984-01-30 |
1985-08-09 |
Icrf Patents Ltd. |
Improvements relating to growth factors
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US5807715A
(en)
*
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5851526A
(en)
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4997913A
(en)
|
1986-06-30 |
1991-03-05 |
Oncogen |
pH-sensitive immunoconjugates and methods for their use in tumor therapy
|
IN165717B
(de)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5034223A
(en)
|
1986-10-09 |
1991-07-23 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
US5071773A
(en)
|
1986-10-24 |
1991-12-10 |
The Salk Institute For Biological Studies |
Hormone receptor-related bioassays
|
US5047324A
(en)
|
1986-12-09 |
1991-09-10 |
Miles Inc. |
Substantially pure enzyme-antibody conjugate preparations
|
US5332837A
(en)
|
1986-12-19 |
1994-07-26 |
The Upjohn Company |
CC-1065 analogs
|
US4952394A
(en)
|
1987-11-23 |
1990-08-28 |
Bristol-Myers Company |
Drug-monoclonal antibody conjugates
|
US4981784A
(en)
|
1987-12-02 |
1991-01-01 |
The Salk Institute For Biological Studies |
Retinoic acid receptor method
|
US5563250A
(en)
|
1987-12-02 |
1996-10-08 |
Neorx Corporation |
Cleavable conjugates for the delivery and release of agents in native form
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
US4937183A
(en)
|
1988-02-03 |
1990-06-26 |
Cytogen Corporation |
Method for the preparation of antibody-fragment conjugates
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
EP0329184A3
(de)
|
1988-02-19 |
1990-05-23 |
Neorx Corporation |
Antimere und antimere Konjugation
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
US5028697A
(en)
|
1988-08-08 |
1991-07-02 |
Eli Lilly And Company |
Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
|
JP3380237B2
(ja)
|
1988-09-12 |
2003-02-24 |
ファルマシア・アンド・アップジョン・カンパニー |
2のcpiサブユニットを有する新規cc―1065アナログ類
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
US5171563A
(en)
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
EP0440740B1
(de)
|
1988-10-12 |
1993-09-22 |
Centocor, Inc. |
Radiotherapeutische immunokonjugate, etikettiert mit iod-125
|
CA2006408A1
(en)
|
1988-12-27 |
1990-06-27 |
Susumu Iwasa |
Bispecific monoclonal antibody, its production and use
|
US5217713A
(en)
|
1988-12-27 |
1993-06-08 |
Takeda Chemical Industries, Ltd. |
Cytotoxic bispecific monoclonal antibody, its production and use
|
US5013547A
(en)
|
1989-02-07 |
1991-05-07 |
Erbamont, Inc. |
Anticancer drug - antibody conjugates and method for preparing same
|
US6020145A
(en)
|
1989-06-30 |
2000-02-01 |
Bristol-Myers Squibb Company |
Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
|
US5980896A
(en)
|
1989-06-30 |
1999-11-09 |
Bristol-Myers Squibb Company |
Antibodies reactive with human carcinomas
|
US5332567A
(en)
|
1989-08-24 |
1994-07-26 |
Immunomedics |
Detection and treatment of infections with immunoconjugates
|
CA2066428C
(en)
*
|
1989-09-08 |
2000-11-28 |
Bert Vogelstein |
Structural alterations of the egf receptor gene in human gliomas
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5459061A
(en)
*
|
1990-01-26 |
1995-10-17 |
W. Alton Jones Cell Science Center, Inc. |
Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
|
JPH05504481A
(ja)
|
1990-02-20 |
1993-07-15 |
クールター コーポレイション |
改良された抗体―酵素直接接合体及びその製造方法
|
WO1991016350A1
(en)
|
1990-04-20 |
1991-10-31 |
Ludwig Institute For Cancer Research |
Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
|
CA2078118C
(en)
|
1990-04-25 |
1999-11-16 |
Paul A. Aristoff |
Cc-1065 analogs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US6248332B1
(en)
|
1990-10-05 |
2001-06-19 |
Medarex, Inc. |
Targeted immunostimulation with bispecific reagents
|
JPH04334377A
(ja)
|
1990-12-31 |
1992-11-20 |
Akzo Nv |
酸−不安定性リンカー分子
|
JP3854306B2
(ja)
|
1991-03-06 |
2006-12-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
ヒト化及びキメラモノクローナル抗体
|
ES2134212T3
(es)
*
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
|
EP0519596B1
(de)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
DK1024191T3
(da)
|
1991-12-02 |
2008-12-08 |
Medical Res Council |
Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
DK0586002T3
(da)
|
1992-08-18 |
2000-06-19 |
Centro Inmunologia Molecular |
Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5674977A
(en)
|
1993-02-05 |
1997-10-07 |
The Ontario Cancer Institute |
Branched synthetic peptide conjugate
|
US5556623A
(en)
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5443953A
(en)
|
1993-12-08 |
1995-08-22 |
Immunomedics, Inc. |
Preparation and use of immunoconjugates
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
AU692239B2
(en)
|
1994-03-07 |
1998-06-04 |
Medarex, Inc. |
Bispecific molecules having clinical utilities
|
PT699237E
(pt)
|
1994-03-17 |
2003-07-31 |
Merck Patent Gmbh |
Fvs de cadeia anti-egfr e anticorpos anti-egfr
|
US5612474A
(en)
|
1994-06-30 |
1997-03-18 |
Eli Lilly And Company |
Acid labile immunoconjugate intermediates
|
CU22615A1
(es)
|
1994-06-30 |
2000-02-10 |
Centro Inmunologia Molecular |
Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
|
US5911995A
(en)
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
CA2206343C
(en)
|
1994-11-28 |
2009-04-07 |
Thomas Jefferson University |
Reagents and processes for targeting mutant epidermal growth factor receptors
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
WO1996040662A2
(en)
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
CA2222231A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
NZ321172A
(en)
|
1995-10-03 |
2000-02-28 |
Scripps Research Inst |
CBI analogs of CC-1065 and the duocarmycins
|
US6699715B1
(en)
|
1995-11-30 |
2004-03-02 |
Bristol-Myers Squibb Co. |
Modified sFv molecules which mediate adhesion between cells and uses thereof
|
JP2000503639A
(ja)
|
1995-12-22 |
2000-03-28 |
ブリストル―マイヤーズ スクイブ カンパニー |
分枝ヒドラゾンのリンカー類
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
US5708156A
(en)
*
|
1996-05-31 |
1998-01-13 |
Ilekis; John V. |
Epidermal growth factor receptor-like gene product and its uses
|
NZ332960A
(en)
|
1996-05-31 |
2000-05-26 |
Scripps Research Inst |
tetrahydro-cyclopropan[c]benz[e]-indol-4-one and tetrahydro-cyclopropan[c]benzo[e]-indole derivatives and medicaments
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
US5942602A
(en)
|
1997-02-13 |
1999-08-24 |
Schering Aktiengessellschaft |
Growth factor receptor antibodies
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
JP2002503228A
(ja)
|
1997-05-22 |
2002-01-29 |
ザ スクリップス リサーチ インスティテュート |
デュオカルマイシンおよびcc−1065の類似体
|
ATE266667T1
(de)
*
|
1997-09-12 |
2004-05-15 |
Lumigen Inc |
Neue verbindungen zur erzeugung von chemilumineszenz mit hilfe einer peroxidase
|
US6262271B1
(en)
|
1997-10-14 |
2001-07-17 |
The Scripps Research Institute |
ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins
|
JP2001525382A
(ja)
|
1997-12-08 |
2001-12-11 |
ザ スクリップス リサーチ インスティテュート |
Cc−1065/デュオカルマイシン類似体の合成
|
US6464686B1
(en)
|
1998-01-21 |
2002-10-15 |
Abbott Laboratories |
Polyurethane feeding tube and associated adaptors
|
US7553809B2
(en)
*
|
1998-02-06 |
2009-06-30 |
Ilexus Pty Limited |
Fc receptor modulators and uses thereof
|
BR9907964A
(pt)
*
|
1998-02-06 |
2000-10-17 |
Ilexus Pty Limited |
Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
JP2002512776A
(ja)
|
1998-04-28 |
2002-05-08 |
スミスクライン・ビーチャム・コーポレイション |
免疫原性の低下したモノクローナル抗体
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
AUPP380498A0
(en)
*
|
1998-05-29 |
1998-06-25 |
Biomolecular Research Institute Limited |
Egf receptor agonists and antagonists
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US20030215387A1
(en)
|
1998-09-04 |
2003-11-20 |
Peter Harrison |
Bifunctional antibodies and their use in targeting anti-tumour agents
|
CN1189166C
(zh)
*
|
1998-09-11 |
2005-02-16 |
伊来克萨斯独资有限公司 |
Fc受体调节剂及其应用
|
US7396810B1
(en)
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
BR0010524A
(pt)
|
1999-05-14 |
2002-05-28 |
Imclone Systems Inc |
Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
AU765588C
(en)
|
1999-11-24 |
2004-12-16 |
Immunogen, Inc. |
Cytotoxic agents comprising taxanes and their therapeutic use
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
EP1266009B1
(de)
|
2000-02-25 |
2008-12-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
|
EP1276771A4
(de)
|
2000-03-10 |
2003-06-04 |
Thomas Jefferson Univarsity |
Empfindlicher nachweis von egfr-mutanten und wildtyp durch spezifische elisa-nachweise in jeglicher biologischer probe
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
US6495599B2
(en)
|
2000-04-13 |
2002-12-17 |
Abbott Laboratories |
Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
|
AU2001273983A1
(en)
|
2000-05-02 |
2001-11-12 |
Lutz F. Tietze |
Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
|
CN102698265A
(zh)
|
2000-05-19 |
2012-10-03 |
杰南技术公司 |
用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
AUPQ841800A0
(en)
*
|
2000-06-28 |
2000-07-20 |
Biomolecular Research Institute Limited |
Truncated egf receptor
|
JP2004527456A
(ja)
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Egf受容体拮抗剤による過増殖性の疾患の治療
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
AR030612A1
(es)
|
2000-09-12 |
2003-08-27 |
Smithkline Beecham Corp |
Procedimiento e intermedios
|
US6660742B2
(en)
|
2000-09-19 |
2003-12-09 |
Taiho Pharmaceutical Co. Ltd. |
Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins
|
DE10048417A1
(de)
|
2000-09-29 |
2002-04-11 |
Roche Diagnostics Gmbh |
Verbindungen mit verzweigtem Linker
|
JP2004511479A
(ja)
*
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
RU2297245C2
(ru)
|
2001-02-19 |
2007-04-20 |
Мерк Патент Гмбх |
Модифицированные анти-egfr антитела с уменьшенной иммуногенностью
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US20020156274A1
(en)
|
2001-03-16 |
2002-10-24 |
Terfloth Gerald J. |
Process for preparing maytansinol
|
EP1243276A1
(de)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Langgestreckte und mehrfachige Abstandhaltern enthaltende aktivierbare Prodroge
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
CA2449166A1
(en)
|
2001-05-08 |
2002-11-14 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Combination therapy using anti-egfr antibodies and anti-hormonal agents
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
US7129261B2
(en)
|
2001-05-31 |
2006-10-31 |
Medarex, Inc. |
Cytotoxic agents
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
CN100497389C
(zh)
|
2001-06-13 |
2009-06-10 |
根马布股份公司 |
表皮生长因子受体(egfr)的人单克隆抗体
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
US20050107595A1
(en)
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP1421113A4
(de)
|
2001-08-03 |
2005-04-13 |
Commw Scient Ind Res Org |
Auf der kristallstruktur des egf-rezeptors basierendes screening-verfahren
|
DE10138876B4
(de)
|
2001-08-08 |
2008-11-06 |
Forschungszentrum Jülich GmbH |
Genetisch modifizierte zyklisch-Nukleotid-gesteuerte lonenkanäle und deren Verwendung
|
JP2005502703A
(ja)
|
2001-09-07 |
2005-01-27 |
ザ スクリプス リサーチ インスティテュート |
Cc−1065およびデュオカルマイシンのcbi類似体
|
US20030109682A1
(en)
|
2001-09-07 |
2003-06-12 |
Daniel Santi |
Maytansines and maytansine conjugates
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
WO2003045312A2
(en)
|
2001-11-21 |
2003-06-05 |
University Of Washington |
Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
US20050031627A1
(en)
|
2002-01-03 |
2005-02-10 |
Mazzola Gregory J |
Methods for preparing immunoconjugates
|
US6790954B2
(en)
|
2002-01-29 |
2004-09-14 |
Immunogen, Inc. |
Mutant Actinosynnema pretiosum strain with increased maytansinoid production
|
CA2479306A1
(en)
|
2002-03-19 |
2003-10-02 |
The Penn State Research Foundation |
Egfr ligands and methods of use
|
US6534660B1
(en)
|
2002-04-05 |
2003-03-18 |
Immunogen, Inc. |
CC-1065 analog synthesis
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
JP2005525423A
(ja)
|
2002-05-13 |
2005-08-25 |
スミスクライン・ビーチャム・コーポレイション |
メイタンシノールの調製方法
|
US6596757B1
(en)
|
2002-05-14 |
2003-07-22 |
Immunogen Inc. |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
|
EP1575491A4
(de)
|
2002-05-20 |
2006-09-27 |
Abgenix Inc |
Behandlung von nierenkarzinomen mit antikörpern gegen egfr
|
WO2003101491A1
(fr)
|
2002-06-03 |
2003-12-11 |
Mitsubishi Pharma Corporation |
Moyens preventifs et/ou therapeutiques destines a des sujets presentant l'expression ou l'activation de her2 et/ou egfr
|
PT1517921E
(pt)
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
Ligandos duplamente especificos com semi-vida no soro aumentada
|
EP1545613B9
(de)
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
BR0313197A
(pt)
|
2002-08-02 |
2005-08-09 |
Immunogen Inc |
Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
|
EP1542723B1
(de)
|
2002-08-16 |
2011-02-23 |
ImmunoGen, Inc. |
Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
|
AU2003259913A1
(en)
|
2002-08-19 |
2004-03-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP1549345A1
(de)
|
2002-10-10 |
2005-07-06 |
MERCK PATENT GmbH |
Bispezifische anti-erb-b-antik rper und ihre verwendung in der tumortherapie
|
EP1560599A1
(de)
|
2002-11-14 |
2005-08-10 |
Syntarga B.V. |
Prodrogen die aus mehrfachen selbstzerstörenden spacer aufgebaut sind
|
US20040147428A1
(en)
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
US20040202666A1
(en)
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
EP1622941A2
(de)
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Methode zur produktion von anti-egfr antikörpern
|
CA2450289A1
(en)
|
2003-03-20 |
2005-05-19 |
Imclone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
US7432088B2
(en)
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
WO2004101767A2
(en)
|
2003-05-13 |
2004-11-25 |
The Scripps Research Institute |
Cbi analogues of the duocarmycins and cc-1065
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
KR101424624B1
(ko)
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
BRPI0411852A
(pt)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
EP1701979A2
(de)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Optimierte antikörper gegen den rezeptor des epidermalen wachstumsfaktors
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
WO2005070457A1
(en)
|
2004-01-23 |
2005-08-04 |
Seattle Genetics, Inc. |
Melphalan prodrugs
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
EP1718667B1
(de)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclische, selbst-immolative linker und konjugate
|
WO2005084390A2
(en)
|
2004-03-02 |
2005-09-15 |
Seattle Genetics, Inc. |
Partially loaded antibodies and methods of their conjugation
|
TW200533339A
(en)
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
EP2053062A1
(de)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobinvarianten außerhalb der Fc-Region
|
KR101347613B1
(ko)
|
2004-03-31 |
2014-01-06 |
다나-파버 캔서 인스티튜트 인크. |
암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브 및 프라이머쌍
|
WO2005099754A2
(en)
|
2004-04-14 |
2005-10-27 |
The Ohio State University Research Foundation |
Maytansinoid analogs as antitumor agents
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
EP1747021B1
(de)
|
2004-05-19 |
2015-09-09 |
E. R. Squibb & Sons, L.L.C. |
Selbstimmolative verbinder und arzneimittelkonjugate
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
EP2592155B2
(de)
|
2004-06-04 |
2019-09-11 |
Genentech, Inc. |
EGFR-Mutationen
|
US20060029574A1
(en)
*
|
2004-08-06 |
2006-02-09 |
Board Of Regents, The University Of Texas System |
Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
|
EP1791565B1
(de)
|
2004-09-23 |
2016-04-20 |
Genentech, Inc. |
Zystein-modifizierte Antikörper und Konjugate
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8288352B2
(en)
|
2004-11-12 |
2012-10-16 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
WO2006065533A2
(en)
|
2004-11-29 |
2006-06-22 |
Seattle Genetics, Inc. |
Engineered antibodies and immunoconjugates
|
US20070134243A1
(en)
|
2004-12-01 |
2007-06-14 |
Gazzard Lewis J |
Antibody drug conjugates and methods
|
ZA200704796B
(en)
|
2004-12-07 |
2008-11-26 |
Genentech Inc |
Selecting patients for therapy with a HER inhibitor
|
EP1688415A1
(de)
|
2004-12-07 |
2006-08-09 |
Aventis Pharma S.A. |
Cytotoxische Wirkstoffe auf Basis von C2-modifizierten Taxanen
|
EP1669358A1
(de)
|
2004-12-07 |
2006-06-14 |
Aventis Pharma S.A. |
Cytotoxische Wirkstoffen auf Basis von neuen Taxanen
|
US7301019B2
(en)
|
2005-01-21 |
2007-11-27 |
Immunogen, Inc. |
Method for the preparation of maytansinoid esters
|
AU2006213662B2
(en)
|
2005-02-11 |
2010-08-05 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
BRPI0609615A2
(pt)
|
2005-04-01 |
2010-04-27 |
Amgen Inc |
métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
CA2614436C
(en)
|
2005-07-07 |
2016-05-17 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
AU2006269940C1
(en)
|
2005-07-18 |
2013-11-07 |
Seagen Inc. |
Beta-glucuronide-linker drug conjugates
|
NZ623901A
(en)
|
2005-08-03 |
2015-10-30 |
Immunogen Inc |
Immunoconjugate formulations
|
WO2007018431A2
(en)
|
2005-08-05 |
2007-02-15 |
Syntarga B.V. |
Triazole-containing releasable linkers and conjugates comprising the same
|
WO2007021674A2
(en)
|
2005-08-09 |
2007-02-22 |
Millennium Pharmaceuticals, Inc. |
Method of acylating maytansinol with chiral amino acids
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AU2006283726C1
(en)
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
ES2283192B1
(es)
|
2005-09-16 |
2008-09-16 |
GAMESA INNOVATION & TECHNOLOGY, S.L. |
Metodo de montaje de elementos en el interior de la torre de un aerogenerador.
|
CN101312748A
(zh)
|
2005-09-26 |
2008-11-26 |
梅达莱克斯公司 |
抗体-药物轭合物和使用方法
|
ES2375843T3
(es)
|
2005-10-26 |
2012-03-06 |
Medarex, Inc. |
Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
|
US7411063B2
(en)
|
2005-11-08 |
2008-08-12 |
Immunogen, Inc. |
Process for preparation of maytansinol
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
SI1948180T1
(sl)
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
DE602006013029D1
(de)
|
2005-11-12 |
2010-04-29 |
Lilly Co Eli |
Anti-egfr-antikörper
|
EP1968633B2
(de)
|
2006-01-04 |
2017-11-01 |
Institut National de la Santé et de la Recherche Medicale |
Kombinationstherapie mit anti-egfr und anti-her2-antikörpern
|
RU2489423C2
(ru)
|
2006-02-02 |
2013-08-10 |
Синтарга Б.В. |
Водорастворимые аналоги сс-1065 и их конъюгаты
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
WO2007103288A2
(en)
|
2006-03-02 |
2007-09-13 |
Seattle Genetics, Inc. |
Engineered antibody drug conjugates
|
EP1832577A1
(de)
|
2006-03-07 |
2007-09-12 |
Sanofi-Aventis |
Verbesserte Pro-Pharmaka von CC-1065-Analoga
|
JP5372737B2
(ja)
|
2006-03-13 |
2013-12-18 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
Egfrキナーゼ阻害剤およびegfrキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
|
CA2664327A1
(en)
|
2006-09-15 |
2008-03-20 |
Lifescience Pharmaceuticals |
Method for detecting and treating skin disorders
|
JP2010509234A
(ja)
|
2006-11-02 |
2010-03-25 |
シアトル ジェネティックス, インコーポレイテッド |
新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
|
US7790164B2
(en)
|
2006-11-14 |
2010-09-07 |
Van Andel Research Institute |
Fragments of antibodies to epidermal growth factor receptor and methods of their use
|
CA2670315A1
(en)
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of California |
Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
US20100322939A1
(en)
|
2007-06-21 |
2010-12-23 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
US8680293B2
(en)
|
2007-08-01 |
2014-03-25 |
Syntarga B.V. |
Substituted CC-1065 analogs and their conjugates
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
US20090269343A1
(en)
|
2008-04-11 |
2009-10-29 |
Duke University |
Dual Specific Immunotoxin for Brain Tumor Therapy
|
US8236319B2
(en)
|
2008-04-30 |
2012-08-07 |
Immunogen, Inc. |
Cross-linkers and their uses
|
RU2010153578A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
EP3360879A1
(de)
|
2009-02-05 |
2018-08-15 |
ImmunoGen, Inc. |
Benzodiazepinderivate als cytotoxischen agenten
|
RU2011148918A
(ru)
|
2009-05-01 |
2013-06-10 |
Эбботт Лэборетриз |
Иммуноглобулин с двумя вариабельными доменами и его применение
|
JP5680087B2
(ja)
|
2009-09-22 |
2015-03-04 |
シャンハイ・イージェー・バイオテクノロジー・カンパニー、リミテッドShanghai Yijie Biotechnology Co.,Ltd |
特異的結合タンパク質およびその使用
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US9209965B2
(en)
|
2014-01-14 |
2015-12-08 |
Microsemi Semiconductor Ulc |
Network interface with clock recovery module on line card
|